A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Todd A. Fehniger*, Marcus P. Watkins, Nkiruka Ezenwajiaku, Fei Wan, David D. Hurd, Amanda F. Cashen, Kristie A. Blum, Andre Goy, Timothy S. Fenske, Nina D. Wagner-Johnston, Kenneth Carson, Marilyn J. Siegel, David Russler-Germain, Stephanie E. Schneider, Neha Mehta-Shah, Brad Kahl, Nancy L. Bartlett*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)953-957
Number of pages5
JournalHaematologica
Volume109
Issue number3
DOIs
StatePublished - Mar 2024

Funding

We thank all study site personnel as well as the patients and their families for participation in this study. This study was supported in part by Celgene/BMS, the ASCO Foundation (to TAF), the Foundation for Barnes-Jewish Hospital Steinback Fund (to NLB), Siteman Cancer Center Team Science Award (P30 CA091842) (to TAF and BK). The authors recognize the support of the Biostatistics Core, Clinical Trials Core, Imaging Response Assessment Team, and Tissue Procurement Core of the Siteman Cancer Center (P30 CA091842) and the Clinical and Translational Science Award (CTSA) grant (UL1 TR000448).

ASJC Scopus subject areas

  • Hematology

Cite this